Dental Mesenchymal Stem Cell-Based Translational Regenerative Dentistry: From Artificial to Biological Replacement

Mona K. Marei 1,2 and Rania M. El Backly 2,3*

1 Department of Removable Prosthodontics, Faculty of Dentistry, Alexandria University, Alexandria, Egypt, 2 Tissue Engineering Laboratories, Faculty of Dentistry, Alexandria University, Alexandria, Egypt, 3 Endodontics, Conservative Dentistry Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt

Dentistry is a continuously changing field that has witnessed much advancement in the past century. Prosthodontics is that branch of dentistry that deals with replacing missing teeth using either fixed or removable appliances in an attempt to simulate natural tooth function. Although such “replacement therapies” appear to be easy and economic they fall short of ever coming close to their natural counterparts. Complications that arise often lead to failures and frequent repairs of such devices which seldom allow true physiological function of dental and oral-maxillofacial tissues. Such factors can critically affect the quality of life of an individual. The market for dental implants is continuously growing with huge economic revenues. Unfortunately, such treatments are again associated with frequent problems such as peri-implantitis resulting in an eventual loss or replacement of implants. This is particularly influential for patients having co-morbid diseases such as diabetes or osteoporosis and in association with smoking and other conditions that undoubtedly affect the final treatment outcome. The advent of tissue engineering and regenerative medicine therapies along with the enormous strides taken in their associated interdisciplinary fields such as stem cell therapy, biomaterial development, and others may open arenas to enhancing tissue regeneration via designing and construction of patient-specific biological and/or biomimetic substitutes. This review will overview current strategies in regenerative dentistry while overviewing key roles of dental mesenchymal stem cells particularly those of the dental pulp, until paving the way to precision/translational regenerative medicine therapies for future clinical use.

Keywords: prosthodontics, biological replacement, dental pulp stem cells, peri-implantitis, translational regenerative dentistry

INTRODUCTION

Prosthodontics is “the dental specialty pertaining to the diagnosis, treatment planning, rehabilitation and maintenance of the oral function, comfort, appearance, and health of patients with clinical conditions associated with missing or deficient teeth and/or maxillofacial tissues using biocompatible substitutes” (Academy of Prosthodontics, 2005). Through the years, materials and techniques have improved to enhance the outcome of appearance, mastication, phonetics, and function of millions of patients all around the world (Ellis et al., 2010; Behr et al., 2012; Lynch, 2012).
For example, implant-supported dentures have definitely upgraded the level of patient satisfaction over the past 20 years as compared to conventional removable dentures (Sanchez-Siles et al., 2018). The advancement of digital techniques employing computer-aided designing and computer-aided manufacturing (CAD/CAM) has also enhanced the ease and precision of replacement prosthetics such as removable partial dentures (Ye et al., 2017). Computer-aided designing techniques have also paved the way to major improvements in the surgical planning and placement of implants and have increased the precision and as such the predictability of prosthetic treatment outcomes (Schnutenhaus et al., 2018).

Although such conventional artificial replacements are continuously being challenged there is still much room for advancements of such therapies as they will continue to serve thousands if not millions of people particularly of the aging population in the upcoming years. The introduction of zirconia implants has also had a pronounced effect on enhancing the quality of implant-retained prosthetics. A recently published retrospective clinical study has shown that the rehabilitation of edentulous jaws using complete-arch fixed implant-supported zirconia prosthesis with veneered porcelain displayed high survival rates for both the prostheses and the implants with minor complications encountered (Tischler et al., 2018). Current advancements in artificial replacement strategies have also extended to other facial prostheses for management of auricular defects which comprise a major sector of maxillofacial deformities. Again the use of CAD/CAM techniques has greatly facilitated obtaining an auricular prosthetic replacement therapy that is accurate, requires fewer number of visits for the patient and which can have a great impact on improving patients’ quality of life (Yadav et al., 2017).

However, although dental replacement therapy is considered an economic and easy treatment, however, this kind of therapy is associated with various complications resulting in failure, frequent repair, and does not always allow physiological function of dental and oral-maxillofacial tissues, all of which are critical factors that affect quality of life (Bilhan et al., 2012; Dewan et al., 2015). Current therapeutic interventions in dentistry are based on sophisticated biomaterials and dental implants yet, there is an enormous unmet need for all these innovative methods to enable a balance between formation of new dental tissue while maintaining normal physiological function (Albrektsson et al., 2014; Carcuac and Berglundh, 2014; Lindhe and Pacey, 2014; Derks et al., 2016). The Federation of Periodontology has provided a forecast that 80 percent of patients and 50 percent of dental implants will develop peri-implant mucositis in the future. These corresponding figures for peri-implantitis are 28–56 percent of the patients and 12–43 percent of the implants (Mombelli et al., 2012). A meta-analysis of 504 studies which included 1,497 patients with 6,293 implants reported the prevalence of peri-implant mucositis to be 63.4% of patients and 30.7% of implants. Smokers recorded higher frequency of peri-implant diseases of up to 36.3% (Atieh et al., 2013). The promise of patient-specific substitutes to enhance tissue regeneration has provided a new approach toward addressing the issue of periimplantitis in spite the fact that numerous efforts have been made to develop more predictable methods for treatment of this disease (Khoshkam et al., 2013; Larsson et al., 2016).

When the field of cell therapy “known later on as tissue engineering and regenerative medicine” was introduced 30 years ago, no one believed that it would extend to the dental and maxillofacial region, while the more critical organs and tissues were on the top of the priority list e.g., liver, kidney, heart, etc. If we look today, the most successful applications of tissue engineering and regenerative medicine are skin, cornea, bone, dental pulp, periodontal ligament, and alveolar bone; all related to the dental and head and neck area (Jalali et al., 2014; Chen F. M. et al., 2016; Miller et al., 2016).

THE NATURE OF DENTAL MESENCHYMAL STEM CELLS: SPECIAL FOCUS ON THE DENTAL PULP RESERVOIR

Most of the tissues in the craniofacial region including the dental pulp and periodontal ligament, are of mesenchymal origin yet specifically derived from the neural crest during embryonic development and so they are frequently termed as ectomesenchyme stem cells “EMSC.” These dental EMSC appear not only to be present in permanent teeth but in the deciduous dentition as well particularly in the pulp and periodontium and exist in substantial amounts (La Noce et al., 2014a). In the dental pulp these cells serve to maintain homeostasis by acting as a reservoir for dental pulp fibroblasts, to replace damaged odontoblasts when needed and to produce reparative dentin (Morikawa et al., 2016).

Several similarities exist between dental pulp stem cells (DPSC) and bone marrow-derived mesenchymal stem cells (BMMSC) with both cell types exhibiting a fibroblast-like phenotype in culture and staining positively for mesenchymal cell markers yet negatively for hematopoietic cell markers. Both BMMSC and DPSC have clonogenic and multi-differentiation potentials being able to differentiate into osteogenic, adipogenic, and chondrogenic lineages (Gronthos et al., 2000; Perry et al., 2008). Mesenchymal stem cells have been found to have dual origin; pericytic and non-pericytic. This fact may imply that tissues harboring higher vascularity may provide more stem cells with a “pericytic” origin to the repair process (Feng et al., 2011).

Donor-matching experiments have demonstrated that DPSC contain a bigger population of stem/progenitor cells and have higher population doubling times than BMMSC (Alge et al., 2010). DPSC also had significantly higher alkaline phosphatase activity than BMMSC following osteogenic differentiation, supporting the possibility of using DPSC to regenerate mineralized tissue. Sub-cloned DPSC were shown to retain their ability to proliferate whereas BMMSC did not. As such, researchers have strongly suggested that DPSC populations may possess enhanced features allowing them to be better candidates than BMMSC for tissue engineering applications (Yu et al., 2007; Huang G. T. et al., 2009).

DPSC have also exhibited the ability to differentiate into melanocytes, myocytes, cardiomyocytes, hepatocyte-like cells, and active neurons in vitro. Consistently, the
reconstruction of large-scale cranial bone defects was reported in non-immunocompromised rats (de Mendonca Costa et al., 2008; Graziano et al., 2008). Additionally, a dental pulp cell/collagen sponge biocomplex was able to completely regenerate mandibular bone defects in patients indicating clear evidence that autologous DPSC could be used as an effective therapeutic strategy for the repair of bone defects with minimal risks involved (d’Aquino et al., 2009). In a follow-up for the clinical cases regenerated by DPSC, it was revealed that the regenerated bone was extremely hard and was actually highly vascularized compact rather than spongy bone which represented a non-physiological nature of the regenerated tissue in relation to that site (Giuliani et al., 2013).

The role of DPSCs in bone regeneration around dental implants has also been investigated and showed that this cell population exhibited the highest osteogenic potential as a source for tissue-engineered bone around titanium implants (Yamada et al., 2010). In more critical cases, it was stressed on the safety of using a graft consisting of DPSC, platelet rich plasma gel and tricalcium phosphate as a scaffold in cases of osteoradionecrosis of the mandible (Manimaran et al., 2014).

Although large numbers of basic scientific and clinical researches have demonstrated the potential of DPSC isolated from 3rd molars or incisors to generate mineralized tissue, dentin, periodontal ligament, or dental pulp; their potential has also extended to applications in orthopedic, oral, and maxillofacial reconstruction (Sonoyama et al., 2006; Aurrekoetxea et al., 2015; Khojasteh et al., 2015; Gao et al., 2016; Li et al., 2016). Recently, the possibility that such cells may have applications beyond the scope of the head and neck region has paved the road toward translational regenerative medicine.

**DENTAL MESENCHYMAL STEM CELLS BEYOND REGENERATIVE DENTISTRY**

**Neuro-Regenerative Potential of Dental Mesenchymal Stem Cells**

All types of dental mesenchymal stem cells (MSC) express nestin (neural stem cell marker), in addition to other neural crest stem cell (SC) markers (musashi-1, p75, snail-1, -2, slug, Sox-9, etc.) indicating their embryonic origin. Undifferentiated dental MSCs express markers of both neural stem/progenitor cells and mature neural cells, including SOX-2, tenascin C, ENO-2, MAP2ab, c-FOS, Nestin, Neurofilament (NEF-H and NEF-L), Gliarial Fibrillary Acidic Protein (GFAP), bIII-tubulin, and Microtubule-Associated Protein 2 (MAP-2) (Osathanon et al., 2014; Pall et al., 2017). Indeed, a significant subpopulation of DPSCs was recently demonstrated to have glial origins which confirms the neuroregenerative potential of these cells (Kaukua et al., 2014).

Recent studies have demonstrated that tooth-driven stem cells promoted strong neuroregenerative activities that fulfill many requirements for functional recovery after spinal cord injury. DPSCs and stem cells from human exfoliated deciduous teeth (SHED) can differentiate into functionally active neurons with the ability to express voltage-gated Na+ channels in vitro and in vivo toward neuron-like cells within only 48 h of transplantation (Arthur et al., 2008; Martens et al., 2014). DPSC-differentiated Schwann cells have also recently been shown to effectively participate in neural tissue regeneration providing a promising tool for peripheral nerve tissue repair (Sanen et al., 2017).

Multiple mechanisms of action involved in the neuroregenerative potential of these cells have been observed. The first is that these cells could inhibit apoptosis of neurons, astrocytes, and oligodendrocytes, which directly improved the preservation of neuronal filaments and myelin sheaths. Second, they inhibited the expression of multiple axon growth inhibitors such as chondroitin sulfate proteoglycan and myelin-associated glycoprotein, via paracrine mechanisms which directly promoted the regeneration of transected axons. They could then replace the lost cells by differentiating into mature oligodendrocytes (Sakai et al., 2012; Yamagata et al., 2013).

**Dental Mesenchymal Stem Cells: A Fountain of Youth**

Although mesenchymal stem cells are promising tools for cell-based tissue engineering strategies, the decline in their cellular proliferation, differentiation potential as well as their regenerative ability with increasing donor age is a valid limitation. The vital role of bone marrow MSCs in cell-based therapies is shown through their immunomodulatory, trophic, and paracrine functions that may have the greatest in vivo therapeutic impact however, these functions have been demonstrated to be age-dependent (Fafian-Labora et al., 2015).

Though DPSC and BM-MSC share many common features, there are differences. The ability to form dental tissues and differentiate into odontoblasts are unique to DPSCs. Investigation into the effects of age on cell source is becoming some important issue especially as older patients become the recipients of procedures for regenerative therapy. With increasing age, the properties of MSCs are altered leading to problems when using autologous MSCs from aged donors for cell-based therapies. Cellular functions of aged BM-MSCs change leading to a reduction in responsiveness to biological and mechanical signals which are related to increased oxidative stress exposure as well as a less dynamic actin cytoskeleton which favor macromolecular damage and senescence. Age-related changes in human MSCs include increases in apoptosis in addition to upregulation of the p53 pathway as well as decreased proliferation and osteogenic differentiation abilities (Zhou et al., 2008; Kasper et al., 2009).

When compared to BMSCs, research data suggested there is no significant change in the DPSC percentage with age, yet, with aging the amount of present DPSCs in the tooth likely decreases. This is a result of age-related changes leading to reduced volume of pulp tissue, deposition of dentin internally, dystrophic calcification within the vascular components, and an increase in the fibrous component of the dental pulp. Some studies have shown that with increased age, there is a decrease in the proliferative capacity of DPSCs as well as their osteogenic/dentinogenic potential. Human DPSCs from aged donors appear to lose their proliferative and differentiation capabilities with advanced passing. Growing human DPSCs under hypoxic conditions under 3% O₂, appears to have...
succeeded in reversing this deficiency, indicating the possibility to obtain sufficient amounts of DPSCs from older patients (Gronthos et al., 2002; Iida et al., 2010).

Indeed, although there is a decrease in the proliferative capacity of DPSC by age this can be modulated by the extrinsic microenvironment. Another important matter is that aging can negatively impact neurogenic differentiation in human DSCs, but the activation of Wnt/β-catenin can reverse this age-associated decline in neurogenic differentiation. This may support the therapeutic application of these cells for treating nerve injury and neurodegenerative diseases (Feng et al., 2013).

In a nerve guide tube model of PLGA, DPSCs were able to promoted 7-mm-long facial nerve gap repair in vivo. Cultured dental pulp-derived cells produced neurotrophic factors, such as nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor, all of which are key elements to protect from facial motor neuron death and promote peripheral nerve regeneration (Sasaki et al., 2011; Yamamoto et al., 2016).

In a recent study aiming to more precisely identify the MSC populations present in the human dental pulp upon passaging, it was found that there was progressive increase in the number of (CD56-Neural Cell Adhesion Molecule) with passages in vitro. CD56 is a cell adhesion molecule which belongs to the superfamily of immunoglobulin receptors. It is abundantly expressed in the central nervous systems and hence it mediates several neuronal functions by controlling intercellular adhesion, neurite outgrowth, and cell migration, proliferation, survival and differentiation; all of which are characteristics of cells migrating from the cephalic neural crest (Ducret et al., 2016).

Mesenchymal stem cells from dental origins other than pulp tissue have been shown to be affected by donor age in regards to proliferation, migration, and differentiation potential as with periodontal stem cells (Zhang et al., 2012). The effect of aging on the regenerative potential of DPSCs has also been investigated thoroughly in an ischemic hindlimb and an ectopic tooth root model in order to determine its influence on the mobilization of specific subpopulations of DPSC when subjected to a granulocyte-colony stimulating factor (G-CSF) protocol. The results indicated that mobilized DPSCs from aged donors were similar to those from young donors in their capacities for migration, differentiation, and expression of angiogenic/neurotrophic factors. Their trophic effects on proliferation and migration, and anti-apoptotic effects were also comparable indicating that this population maintains its properties irrespective of age. Pulp mesenchymal stem cells from aged and young donors expressed stem cell markers as CXCR4, GCSFR, and CD105. The mobilization isolation protocol using granulocyte-colony stimulating factor allowed DPSCs to overcome the decrease in stemness occurring with age (Horibe et al., 2014).

**Dental Stem Cell-Paracrine-Mediated Functions for Regenerative Applications**

These previously mentioned characteristics suggest an immense utility for stem cells from the dental pulp in clinical applications in regenerative dentistry as well as ischemic diseases by autologous cell transplantation. DPSCs were able to induce cardiac repair in the absence of cell differentiation, which occurred through an increase in vessel numbers and a reduction in the size of the infarcted area as it was demonstrated before with bone marrow mesenchymal stem cells. Their ability to secrete proangiogenic VEGF improved cardiac function by reversing the cardiac ratio of angiopoietin-1 to angiopoietin-2 and antiapoptotic factors (Gandia et al., 2008). Human DPSC-induced paracrine-mediated angiogenesis took place via production of high amounts of angiogenic molecules, stimulation of endothelial cell migration by activation of the PI3K–AKT and MEK–ERK pathways and thus significantly induced the formation of blood vessels, highlighting the suitability of DPSCs for treatment of stroke and myocardial infarction; diseases in which a reduction of angiogenesis is clear (Tatullo et al., 2015).

Paracrine-mediated angiogenesis by DPSCs is associated with the secretion of a broad range of regulatory proteins such as platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF), either in normal conditions or in response to noxious stimuli, such as injury or hypoxia. Other angiogenesis-promoting factors that have been detected in DPSCs are angiogenin (ANG), angiopoietin-1 (ANGPT1), colony-stimulating factor (CSF), dipeptidyl peptidase IV (DPPIV), endothelin-1 (EDN1), interleukin-8 (IL-8), insulin-like growth factor binding protein-3 (IGFBP3), monocyte chemoattractant protein-1 (MCP-1), and urokinase-type plasminogen activator (uPA) (Janebodin et al., 2013).

Additionally, stem cells from pulps of human exfoliated deciduous teeth (SHED) have bone marrow-derived MSC-like characteristics. An *in vivo* transplantation study showed that SHED could produce dental pulp-like tissue with the beneficial paracrine effects that are involved in immunomodulation and angiogenesis; characteristics that will enhance the clinical potential of dental mesenchymal stem cells to treat a variety of pathologies (Miura et al., 2003; Werle et al., 2016; Zhang et al., 2016). Although SHED are derived from deciduous teeth, the developmental and anatomical similarities between the deciduous and adult dental pulps has shown that SHED may also have perivascular origins and thus pericyte-like characteristics. Indeed, *in-vivo* studies have demonstrated that SHED were able to form functional vessel-like structures upon transplantation (Kim et al., 2016).

While DPSCs lose their plasticity through passaging, several investigations have provided enough evidence that SHED can retain their characteristics. Results from DNA microarray analysis revealed that there were 4386 genes that were expressed differently between DPSCs and SHED by 2.0-fold or more. SHED expressed higher levels of genes related to pluripotency (OCT4, SOX2, NANOG, and REX-1), cell proliferation, and extracellular matrix, including several cytokines such as fibroblast growth factor and tumor growth factor b (Kerkis and Caplan, 2012; Kaukua et al., 2015; Majumdar et al., 2016).

Studies in recent years have resulted in the recognition of a paracrine function of stem cells, and have suggested that stem cell transplantation may also be regarded as cell-based cytokine therapy. Exogenously delivered DPSC and
SHED secrete factors, such as vascular endothelial growth factor, chemokine stromal-cell-derived factor-1, nerve growth factor, brain-derived neurotrophic factor, and glial cell-derived neurotrophic factor which highlight their possible mechanism of function. The degree of cytoprotection offered by human DPSCs and conditioned media of human DPSCs was significantly greater compared with human MSCs and conditioned media of human MSCs, suggesting that human DPSCs could be a better therapeutic source for cerebral ischemia. The mechanism underlying this effect was that conditioned media of pulp CD31–side population cells significantly enhanced migration, anti-apoptosis and angiogenesis while having little effect on cell proliferation compared with the non-pulp-derived conditioned media. The proof-of-this concept was documented recently as an inductive microenvironment reconstituted from EDTA soluble chemical components of extracted teeth and the conditioned media of mobilized population DPSCs promoted cell proliferation, migration, and odontoblastic differentiation (Inoue et al., 2013; Hayashi et al., 2015; Song et al., 2015; Kawamura et al., 2016).

Recent work has additionally developed the methodology of intravenous administration of allogeneic dental pulp derived neurosphere cells as an important base for regenerative medicine and indicated that those cells were able to ameliorate the outcomes in focal brain ischemia in rat global cerebral ischemic condition. Since pulp stem cells can be obtained from exfoliated deciduous teeth as SHED or impacted adult wisdom teeth thus, preserved autologous or allogeneic dental pulp could be an attractive source for future regenerative therapy for oral diseases as well as systemic diseases (Kumasaka et al., 2017).

**Dental Mesenchymal Stem Cells: Hope for a Multitude of Systemic Ailments?**

Being able to bank DPSCs obtained from adult third molars after routine extraction or bank SHED, has paved the road to many investigations as a powerful autologous stem cell source for treatment of a variety of ailments. Through gene and protein expression, DPSCs were shown to differentiate effectively into keratocytes in vitro, and to function in vivo without eliciting overt rejection. As a matter of fact, other investigators have provided evidence of DPSC-special characteristics that are similar to epithelial and neural stem cells even more than those of BMSCs (Karaoz et al., 2011; Garzon et al., 2015). DPSCs have been shown to effectively differentiate into keratocytes confirmed by their expression of keratocyte-specific molecules similar to the normal human cornea. This evidence strongly points to the potential translation of DPSCs as an autologous cell source for targeting corneal regeneration (Syed-Picard et al., 2015).

Corneas are the most frequently transplanted tissue worldwide, however, this procedure is successful only if the recipient has a functional stem cell population. As a result, this limits what can be done for those patients with damaged limbal stem cell niches and who have developed limbal stem cell deficiencies because the corneal epithelial layer is no longer maintained (Ricardo et al., 2013). Recent studies have looked at restoring the stem cell population in a way to re-establish a functional limbus (Rahman et al., 2009). Contact lenses were used by many studies not only to correct vision or aesthetics, but also to provide an adequate reservoir for drugs and/or cells to adjust the environment of the cornea (Espandar et al., 2014; Bobba and Di Girolamo, 2016). In a revolutionary step toward routine clinical application, soft contact lenses were used as carriers to deliver DPSCs to enhance corneal epithelium regeneration. Investigators described that the cell/ scaffold construct once transplanted in-vivo, DPSCs had transferred from the contact lenses to the corneal surface and began to express the corneal specific markers cytokeratins 3 and 12. In addition to the expression of these markers, the DPSCs were able to prevent conjunctival cells from growing in the central cornea (Yam et al., 2015; Kushnerev et al., 2016).

Recently DPSCs have been shown to differentiate toward specific neuronal fates upon specific chemical and environmental cues. Co-culturing of DPSCs with rat retinal explants allowed DPSCs to enter into a retinal neuronal fate with upregulated brain-derived neurotrophic factor and retinal markers expression along with induction of the mature photoreceptor gene. From these studies it was suggested that DPSCs could be an enticing source of retinal-like stem cells that can differentiate into retinal neurons and even photoreceptors. This has paved the road to a novel strategy for reversing retinal degeneration (associated with age-related macular degeneration, retinitis pigmentosa, macular dystrophy, artery, or vein occlusion) (Bray et al., 2014; Syed-Picard et al., 2015; Yam et al., 2015).

Dental mesenchymal stem cells also hold great promise for the treatment of diabetes. Indeed, researchers have spent decades trying to find a reliable method to restore functional pancreatic islets that produce insulin. Embryonic or adult bone marrow stem cells have been shown to contribute to b-cell renewal and may help reverse nervous system damage (Janus et al., 2003; Schonhoff et al., 2004; Lee et al., 2006; Koblas et al., 2009; Okura et al., 2009). It has been previously shown that type 1 diabetes could be cured by transplantation of insulin-producing islet cells from a donor pancreas. However, a critical limitation of such an approach is the lack of sufficient donor organs and the side-effects of immunosuppression which have hindered the application of such a therapy and have directed huge efforts to search for alternative sources of islet cells (Shapiro et al., 2000).

Major advances have been made in the understanding of developmental endocrinology that have opened the arena to stem cell therapy via differentiation of mesenchymal stem cells into pancreatic islets. Although there are many sources for MSCs such as umbilical cord blood, bone-marrow, and adipose stem cells that have the potential to differentiate into insulin-producing cells, these sources maybe scarce and still require invasive procedures to obtain them; factors which again have limited their use (Janus et al., 2003; Lee et al., 2006; Koblas et al., 2009; Okura et al., 2009). Accordingly, DPSCs may be considered as an appealing source for MSCs, since their use is not controversial, they are easily accessible and available, and they pose no risk of discomfort for the patient. Researchers have transplanted DPSCs and demonstrated for the first time that these cells have a powerful and long lasting irreversible anti-nociceptive effect in mice with diabetic neuropathic pain. They showed that this effect was hardly
reached by clinically used analgesics and could be explained by the cells’ strong secretion of anti-inflammatory, angiogenic, and neurotrophic factors (Guimaraes et al., 2013; Izumoto-Akita et al., 2015).

Reports have demonstrated many common features among pancreatic β-cells of endodermal origin and those of neurons of ectodermal origin. During pancreatic development, the neural crest is linked with the pancreatic epithelium via Phox2b and Nkx2.2 which form a non-cell-autonomous feedback loop. This loop also regulates the proliferation of the beta-cell population, and thereby impacts insulin-secretory capacity and homeostasis of energy. Although, the neural crest cells do not differentiate into pancreatic islet cells, these cells do contribute indirectly to islet development via a novel non-cell autonomous negative-feedback interaction between the neural crest cells and the pancreatic cells (Schonhoff et al., 2004; Nekrepp et al., 2008).

The previously established intrinsic similarities between neural cells and DPSCs, have suggested that stem cells of dental origin may offer a useful alternative to generate insulin producing cells. Studies have additionally documented the potential of dental mesenchymal stem cells derived from deciduous teeth or periodontal tissues to differentiate into insulin producing cells as a non-invasive source of cells for islet generation that can be used for autologous transplantation for the treatment of children with type 1 diabetes without risk of rejection and calls for banking deciduous teeth for clinical application (Govindasamy et al., 2011; Lee et al., 2014).

Recent work has also indicated that cryopreserved (Cryo-) DPSCs displayed comparable capacity for proliferation and differentiation as fresh-DPSCs. Cryo-DPSC transplantation was as effective as the transplantation of fresh-DPSCs in improving nerve conduction speed and blood flow in diabetic rats. DPSCs showed anti-inflammatory properties as they could ameliorate diabetic polyneuropathy upon transplantation into diabetic rats. These effects were apparent via their ability to modulate the proportions of M1/M2 macrophages in diabetic peripheral nerves (Hata et al., 2015; Omi et al., 2016). As it was mentioned before, SHED express many genes encoding extracellular and cell surface proteins at levels that are 2-folds higher than those in human bone marrow-derived MSCs (Sakai et al., 2012; Feng et al., 2013; Yamagata et al., 2013; Fafian-Labora et al., 2015; Yamamoto et al., 2016). Current data additionally support the fact that treatment with SHED-conditioned media (CM) can directly improve both survival and function of pancreatic β-cells much more than with Bone marrow-CM indicating anti-diabetic effects of the secreted paracrine factors of SHED-CM. These results have opened a new avenue for the treatment of diabetic patients (Izumoto-Akita et al., 2015).

Further important applications of dental mesenchymal stem cells are for treatment of kidney injuries. The anti-inflammatory ability of SHED secreted factors has been shown to promote the proliferation and migration of tubular epithelial cells through a paracrine mechanism in acute kidney injury (Hattori et al., 2015). Another very promising emerging application is in cardiac repair indicating that DPSC transplantation improves regional contractility as well as preventing ventricular remodeling. Ultra-structural analysis of Left Ventricular wall peri-infarct zones showed an increase in cardiomyocyte bundles that reduced infarcted area and a higher proportion of myofibroblasts. It is believed that DPSCs are able to repair infarcted myocardium, due to their ability to secrete pro-angiogenic and anti-apoptotic factors (Gandía et al., 2008). In a recent investigation, SHED-CM protected the heart from acute ischemic injury as it suppressed inflammation and apoptosis. SHED-CM antiapoptotic action was more effective than bone marrow-derived stem cell (BMSC)-CM or adipose-derived stem cell (ADSC)-CM in cardiac myocytes. SHED-CM could attenuate myocyte apoptosis representing an important therapeutic target for ischemic heart disease (Yamaguchi et al., 2015).

Recently, various stem cell populations have also been used to treat muscular dystrophy. The ability of these cells to mobilize host progenitor cells and promote angiogenesis is partly owed to their ability to resist stress but mainly due to their paracrine-mediated effects which directly caused improvement of muscle histopathologies (Gharai beh et al., 2011). In this aspect, human DPSCs have also been employed (Martinez-Sarra et al., 2017) and they have shown capability of supporting the improvement of skeletal muscle regeneration by promoting new blood vessel formation and interacting directly and indirectly with myoblasts as well as promoting the proliferation of myogenic precursor cells within the transplanted muscles. The engraftment of these cells contributed reducing fibrosis within the dystrophic muscle, which further enhanced regeneration (Piscotta et al., 2015).

Another promising application for dental mesenchymal stem cells was the ability to differentiate DPSCs into bladder-associated smooth muscle cells (SMCs) when treated with a combination of conditioned media from bladder SMCs and TGF-β1 (Song et al., 2016). Furthermore, although DPSCs rarely express tendon-related proteins in vitro, such as SCX, EYA2, and TNC; when cultured in 2-D culture dishes researchers have been able to demonstrate that DPSCs could be differentiated into tenogenic-like cells and form more mature tendon-like tissues under mechanical loading in the mouse model (Chen Y. Y. et al., 2016).

**THE ROAD TO TRANSLATIONAL/PRECISION REGENERATIVE MEDICINE**

The field of *precision medicine* which includes "prevention and treatment strategies that take individual variability into account" has been dramatically improved by the recent development of large-scale biologic databases and the advent of computational tools for analyzing large quantities of data. At the forefront of this new era of medicine is the discovery of the human genome sequence that has generated knowledge applicable to span all of health and disease (Collins, 2015; Collins and Varmus, 2015).

The discovery of stem cells has not only revolutionized the study of disease, but also holds major therapeutic value. Through combining stem cell research with new methods to efficiently generate targeted mutations in mammalian cells, a new window for precise diagnosis and treatment has now been opened. The twenty-first century can truly be defined as the century of biology with investments in biomedical research which will optimally
have its rewards on both economy and health. The main objective of biomedical research is to speed up the clinical translation of basic research and eventually to therapeutic strategies to reduce human suffering and minimize health inequalities (Cong et al., 2013; Surkis et al., 2016).

The evolution of patient-specific medicine has witnessed strides of achievement with the dawn of technologies that can reprogram human adult somatic cells into pluripotency or into a different cell type making the study of patient-specific cells a possibility. Having patient-specific cells allows researchers to thoroughly understand the disease mechanisms and also provide a platform for drug testing which could then be followed by upsampling these strategies. There are a handful of stem-cell-based treatments available, such as bone marrow transplantations to treat blood disorders, which have proven beneficial for patients in well-designed clinical trials and are now offered as treatments. In clinical trials, most therapies that utilized adult stem cells and have shown successful results, are shifting to using DPSCs for the same application and have started to show promising results. Clinicians and researchers have demonstrated that 75% of patients with limbal stem-cell deficiency who received limbal stem-cell grafts as corneal transplants, showed successful treatment with follow-up extending up to 10 years (Rama et al., 2010; de Araujo and Gomes, 2015). However, because of the concern of removing the limbus from a healthy eye, with the potential harm to limbal epithelial stem cells during isolation in addition to disruption occurring to the native limbal niche, different protocols have arisen to modify the original technique (Tseng et al., 2010; Ramirez et al., 2015).

With a continuously growing body of evidence demonstrating that the trophic effects of proteins and paracrine factors rather than terminal engraftment are key factors, regenerative medicine appears to offer a factual approach toward transforming healthcare in a true clinical sense. Yet, there are currently many challenges facing the use of cellular products. In most clinical situations, the number of primary donor cells needed for transplantation maybe insufficient to meet the clinical therapeutic level needed and the expansion of cells in culture under good manufacturing process (GMP) conditions is required to address this shortage (Heathman et al., 2015). Autologous cell-based therapies are based on personalized (service-based) medicine in addition to the complexity of upsampling production and delivery of a cost effective autologous cell-based therapy. In fact, delivery of autologous cell-based products can be complex due to the inability to perform long term preservation for transport and delivery (Mason and Dunnill, 2009). Autologous therapies requiring participation by clinicians; partly because of the need for initial patient biopsy and a subsequent surgical restoration phase; have resulted in a smaller scale of clinical trial studies since clinician participation is restricted to autologous procedures. High levels of process and product characterization are required for autologous cell therapies making the establishment of allogeneic cell banks a much more cost effective option (Dodson and Levine, 2015).

Transplantation of hematopoietic stem cells has illustrated success for over 50 years since 1960 and is becoming the standard-of-care for numerous indications. Currently, tissue-specific stem cells have focused on the paradigm shift of replacement of diseased tissue with autologous or allogeneic stem cells (Korbling and Estrov, 2003; Boo et al., 2011).

However, research has shown that the engraftment of implanted cells may not be all that crucial thus opening a new avenue of clinical application for mesenchymal stem cells in immune- and inflammation-mediated diseases. This therapeutic approach relies on indirect effects of mesenchymal stem cells in addition to their direct effects (Griffin et al., 2013; Wang et al., 2016). In turn, this novel direction has urged the shift from autologous to allogeneic cell sources. While the immunomodulatory properties of MSCs were identified few years ago, nearly half “almost 42%” of all registered clinical trials are being conducted for immune-/inflammation mediated diseases with only 32.5% that use autologous sources and over 50.9% of trials using allogeneic sources. It is becoming obvious that the capacity to use allogeneic MSCs has greatly contributed to increased popularity of stem cells (Griffin et al., 2013; Introna et al., 2014; Wang et al., 2016; NIH1).

The current approach of using autologous stem cells is to avoid immune rejection of donor cells that is probable after allogeneic transplantation. However, in spite of promising results, harvesting autologous cells is not without its drawbacks. These include logistic, economic, and timing constraints particularly since the target population for these therapies is likely the elderly who already present for treatment with multiple complex disorders. As previously mentioned there are a number of studies that have shown that mesenchymal stem cells (MSCs) obtained from elderly donors, and those with diabetes may have limited therapeutic potentials. This has opened the avenue for the obvious clinical advantages of universal donor cells from young healthy individuals which could be used for stem cell allotransplantation without the need for immunosuppression. Additionally, serious consequences of replicative senescence in hMSCs are that this phenomenon may impair the secretion of soluble factors in response to the inflammatory microenvironment thus resulting in loss of the immunoregulatory functions of these cells (Zhuo et al., 2010; Bustos et al., 2014).

A series of observations has highlighted the immunomodulatory properties of allogeneic MSCs whereby they are able to survive and differentiate when transplanted in immunocompatible-mismatched recipients. They do not induce a proliferative T-cells response but instead can modulate their function in allogeneic experiments indicating that the hypoimmunogenic pattern is a unique expression pattern of cell-surface antigens on MSCs (Horwitz et al., 2002; Tse et al., 2003; Atoui and Chiu, 2012). Hence, allogeneic “off-the-shelf” therapies maintain long-term stability and by automating the manufacturing process enhanced processing and control can be achieved that dictate the introduction of the universal cell donor and paint the next generation of clinical cell-based therapy trials (Kinkaid et al., 2010; Telukunla et al., 2013; Heathman et al., 2015).

1NIH Clinical Trial Database. Available online at: https://clinicaltrials.gov/ct2/results?term=allogeneic+mesenchymal+stem+cells&Search=Search
The presence of active immune responses in the oral cavity make it a challenging unique environment which inevitably affects periodontal tissue, jaw bone, and tooth regeneration. Due to the highly dynamic inflammatory environment of the oral cavity; dental MSCs, including SHED, SCAP, periodontal ligament stem cells (PDLSCs), and jaw bone MSCs, have shown strong immunomodulatory capacities (Wada et al., 2009; Yamaza et al., 2010, 2011; Ding et al., 2010a; Hieke et al., 2016; Rajan et al., 2016). For example, DPSCs can suppress T lymphocyte growth rate by 18% higher than BM-MSCs, indicating possible superior immunosuppression properties of DSCs (Taš et al., 2016). More importantly, DPSCs can strongly inhibit proliferation of peripheral blood mononuclear cells induced by mitogens in comparable degrees to PDLSCs yet stronger than BMSCs. This effect appears to be modulated by secretion of transforming growth factor-b1. Earlier reports have proven that the addition of DPSCs can inhibit the T-cell response up to 91% while BMSCs allowed only 75% inhibition of T-cell response, highlighting the possible use of DPSCs in different individuals or to be used for immune therapy (Pierdomenico et al., 2005; Ding et al., 2015). The dental pulp of healthy young patients appears to possess the generic MSC phenotype and can strongly inhibit acute allogeneic immune responses resulting from T-lymphocyte stimulation again through their release of TGF-β (Kwack et al., 2017). This provides insight into the potential clinical use of hDPSCs for dental and non-dental tissue regeneration using allogeneic transplantation, that will move the field of stem cell therapy into true clinical application faster than before.

Human dental pulp stem cells (DPSC) are an attractive option for exogenous stem cell therapy and have several advantages for translational cell-based therapy. Teeth are a clinically accessible source especially since many older adults possess their own teeth which could then be used as a source of viable human DPSCs for autologous transplantation. The feasibility that viable DPSCs can still be obtained up to 120 h of tooth storage in phosphate buffered saline (PBS) at 4°C post extraction from a whole tooth and can be obtained from teeth undergoing root canal treatment without the need for extraction; all support the possibility for banking these tissues for regenerative medicine applications (Arthur et al., 2008; Perry et al., 2008; Huang A. H. et al., 2009). This is in addition to the low immunogenic response of DPSCs which could open the door for allogeneic cell grafts. Moreover, as previously mentioned human DPSCs have been shown to have neurogenic potential and to generate functional neurons in addition to their high proliferative capacities (Gronthos et al., 2000; Leong et al., 2012). Clinical banking of DPSCs can be facilitated by storing teeth that have been subjected to minimal processing which also minimizes cost particularly if these cells are not planned for immediate expansion and use (Papaccio et al., 2006; Woods et al., 2009). Additionally, expanded cells can be stored for a minimum of 6 months and even longer at −85°C. SHED isolated from deciduous pulp tissues cryopreserved for over 2 years can maintain their stem cell properties in a way comparable to SHED isolated from fresh tissues (Papaccio et al., 2006; Woods et al., 2009; Ding et al., 2010b; Ma et al., 2012).
Indeed, there is an international call for banking SHED as they require less than one third of the cost of cord blood storage and they are not subject to the same ethical concerns as embryonic stem cells. SHED may also be useful to a certain extent to their immediate family and blood relatives such as grandparents, parents, uncles, and siblings. SHED cells are complementary to stem cells from cord blood (Arora et al., 2009). Although, bone marrow and adipose tissue are considered potential sources of stem/progenitor cells; painful collection protocols, the decline of the amount of stem/progenitor cells with age, the necessity for general anesthesia, the reduced proliferation capacity, and risk of morbidity at the collection site have all encouraged the search for alternatives such as dental mesenchymal stem cells (Huang G. T. et al., 2009; Davies et al., 2015).

Several protocols have been developed to obtain clinical-grade dental pulp stem/progenitor cells (DPSCs) from teeth while avoiding any alteration of their biological properties and preserving the quality of the derived cell-based products.

In conclusion, as the fields of regenerative medicine and dentistry quickly move into an era of personalized and precision therapeutics, the use of dental pulp stem cells for clinical translation will soon become a feasible reality (Figure 1). Dental pulp stem cells represent a versatile and readily available source of stem cells that can be stored efficiently for long periods of time. Dental pulp stem cells not only offer potential treatment for many dental dilemmas but their use may span numerous non-dental applications as well (Table 1). This is an addition to their therapeutic benefits that are elicited not only via their exogenous transplantation but through their paracrine-mediated mechanisms as well. With the development of standardized and optimized clinical good manufacturing process guidelines, both allogenic and autologous use of these cells for therapy may soon become an achievable goal.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**REFERENCES**

Academy of Prosthodontics (2005). The glossary of prosthodontic terms. *J. Prosthet. Dent.* 94, 10–92. doi: 10.1016/j.prosdent.2005.03.013

Albrektsson, T., Dahlén, C., Jemt, T., Sennerby, L., Turri, A., and Wennerberg, A. (2014). Is marginal bone loss around oral implants the result of a provoked foreign body reaction? *Clin. Implant Dent. Relat. Res.* 16, 155–165. doi: 10.1111/cid.12142

### TABLE 1 | A summary of the dental and non-dental therapeutic applications of dental pulp stem cells.

| Dental therapeutic applications | Non-dental therapeutic applications | Benefits | Limitations |
|----------------------------------|-------------------------------------|----------|------------|
| Dentine/Pulp complex regeneration | Spinal cord injury and peripheral nerve tissue repair | Clinically accessible source | May become limited with age |
| Craniofacial bone regeneration | Cardiac repair/angiogenesis and treatment of ischemic disease | Can be banked easily and with low cost | Lack of optimized standardized protocols for isolation and characterization of clinical grade cells |
| Enhancing osseointegration of dental implants | Corneal and retinal regeneration | Higher proliferative and osteogenic differentiation capacities compared to bone marrow mesenchymal stem cells | DPSCs may lose plasticity with passaging as compared to SHED which retain their characteristics |
| Treatment of osteoradionecrosis | Muscular dystrophy and tendon regeneration | Derived from the neural crest | Express pluripotency markers at a lesser degree than SHED |

**REFERENCES**

Academy of Prosthodontics (2005). The glossary of prosthodontic terms. *J. Prosthet. Dent.* 94, 10–92. doi: 10.1016/j.prosdent.2005.03.013

Albrektsson, T., Dahlén, C., Jemt, T., Sennerby, L., Turri, A., and Wennerberg, A. (2014). Is marginal bone loss around oral implants the result of a provoked foreign body reaction? *Clin. Implant Dent. Relat. Res.* 16, 155–165. doi: 10.1111/cid.12142
Alge, D. L., Zhou, D., Adams, L. L., Wyss, B. K., Shadday, M. D., Woods, E. J., et al. (2010). Donor-matched comparison of dental pulp stem cells and bone marrow-derived mesenchymal stem cells in a rat model. *J. Tissue Eng. Regen. Med.* 4, 73–81. doi: 10.1002/term.220

Arora, V., Arora, P., and Munshi, A. K. (2009). Human bone marrow-derived mesenchymal stem cells potential. *Stem Cell Res. Ther.* 10, 1–8. doi: 10.4252/wjsc.v7.i8.806

Arora, V., Arora, P., and Munshi, A. K. (2015). Human bone marrow-derived mesenchymal stem cell/progenitor cells and collagen sponge biocomplexes. *Europ. Cell Res.* 18, 75–83. doi: 10.22203/ecm.v018a07

Davies, O. G., Cooper, P. R., Shelton, R. M., Smith, A. J., and Scheven, B. A. (2015). A comparison of the in vitro mineralisation and dentinogenic potential of mesenchymal stem cells derived from adipose tissue, bone marrow and dental pulp. *J. Bone Miner. Metab.* 33, 371–382. doi: 10.1007/s00774-014-0601-y de Araujo, A. L., and Gomes, J. A. (2015). Corneal stem cells and tissue engineering: current advances and future perspectives. *World J. Stem Cells* 7, 806–814. doi: 10.4252/wjst.v7.i8.806

Atieh, M. A., Alsabeeha, N. H., Faggion, C. M. Jr., and Duncan, W. J. (2013). The composition of human periodontal ligament progenitor cells: implications for bioengineering and the regeneration of craniomaxillofacial tissues. *J. Periodontal. Res.* 84, 1586–1598. doi: 10.1903/jop.2012.120592

Bakka, S., and McAndrew, R. (2010). A pilot study examining the effects of enhanced aesthetics on oral health related quality of life and patient’s satisfaction with complete dentures. *Eur. J. Prosthodont. Restor. Dent.* 18, 116–122. doi: 10.1922/eJPrd_893McAndrew07

Buck, P. M., and Levine, A. D. (2015). Challenges in the translation and commercialization of cell therapies. *BMC Biotechnol.* 15:70. doi: 10.1186/s12896-015-0199-4

Dewar, S. K., Arora, A., Sekhal, M., and Kuhllar, A. (2015). Implant failures: a broader perspective. *J. Dent. Implants* 5, 53–59. doi: 10.4103/0974-6781.154441

Ding, G., Liu, Y., An, Y., Zhang, C., Shi, S., Wang, W., et al. (2010a). Suppression of T cell proliferation by root apical papilla stem cells in vitro. *Cells Tissues Organs* 191, 357–364. doi: 10.1159/000276589

Ding, G., Niu, and Liu, Y. (2015). Dental pulp stem cells suppress the proliferation of lymphocytes via transforming growth factor-beta1. *Hum. Cell* 28, 81–90. doi: 10.1016/s1357-0146-0106-y

Ding, G., Wang, W., Liu, An, Y., Zhang, C., Shi, S., et al. (2010b). Effect of cryopreservation on biological and immunological properties of stem cells from apical papilla. *J. Cell. Physiol.* 223, 415–422. doi: 10.1002/jcp.22050

Dodson, B. P., and Levine, A. D. (2015). Challenges in the translation and commercialization of cell therapies. *BMC Biotechnol.* 15:70. doi: 10.1186/s12896-015-0199-4

Ducut, M., Fabre, H., Degoul, O., Attzeni, G., McGuckin, C., Forraz, N., et al. (2015a). Manufacturing of dental pulp cell-based products from human third molars: current strategies and future investigations. *Front. Physiol.* 6:212. doi: 10.3389/fphys.2015.00213

Ducut, M., Fabre, H., Degoul, O., Attzeni, G., McGuckin, C., Forraz, N., et al. (2016). Immunophenotyping reveals the diversity of human dental pulp mesenchymal stem cells in vivo and their evolution upon in vitro amplification. *Front. Physiol.* 7:122. doi: 10.3389/fphys.2016.00512

Ducut, M., Fabre, H., Farges, J. C., Degoul, O., Attzeni, G., McGuckin, C., et al. (2015b). Production of human dental pulp cells with a medicat manufacturing approach. *J. Endod.* 41, 1492–1499. doi: 10.1016/j.endod.2015.03.017

Ellis, J. S., Thomson, J. M., and McAndrew, R. (2010). A pilot study examining the effects of enhanced aesthetics on oral health related quality of life and patient’s satisfaction with complete dentures. *Eur. J. Prosthodont. Restor. Dent.* 18, 116–122. doi: 10.1922/ejprd.893McAndrew07

Espandar, L., Caldwell, D., Watson, R., Blanco-Mezquita, T., Zhang, S., and Bunnell, B. (2014). Apoptotic and adipose-derived stem cells on scleral contact lens carrier in an animal model of severe acute alkaline burn. *Eye Contact Lens Sci. Technol.* 40, 243–247. doi: 10.1097/ICL.0000000000000045

Eubanks, E. J., Tarle, S. A., and Kaigler, D. (2014). Tooth storage, dental pulp stem cell isolation, and clinical scale expansion without animal serum. *J. Pediatr. Dent.* 40, 652–657. doi: 10.1016/j.jpdr.2014.01.005

Fadlan-Labora, J., Fernandez-Pernas, F., Fuentes, L., De Toro, J., Oreiro, N., Sangiao-Alvarellos, S., et al. (2015). Influence of age on rat bone-marrow mesenchymal stem cells potential. *Sci. Rep.* 5:16765. doi: 10.1038/srep.16765

Feng, J., Jy, S., and Sharpe, P. T. (2011). Dual origin of mesenchymal stem cells contributing to organ growth and repair. *Proc. Natl. Acad. Sci. U.S.A.* 108, 6503–6508. doi: 10.1073/pnas.1015449108

Feng, X., Xing, J., Feng, G., Sang, A., Shen, R., Xu, Y., et al. (2013). Age-dependent impaired neurogenic differentiation capacity of dental stem cell is associated with Wnt/beta-catenin signaling. *Cell. Mol. Neurobiol.* 33, 1023–1031. doi: 10.1007/s10571-013-9965-0

Gandia, C., Arminan, A., Garcia-Verdugo, J. M., Lledo, E., Ruiz, A., Minana, M. D., et al. (2008). Human dental pulp stem cells improve left ventricular function, induce angiogenesis, and reduce infarct size in rats with acute myocardial infarction. *Stem Cells* 26, 638–645. doi: 10.1634/stemcells.2007-0484

Gao, Z. H., Liu, L., Liu, G. L., Wei, F. L., Liu, Y., Liu, Z. H., et al. (2016). Bio-root and implant-based restoration as a tooth replacement alternative. *J. Dent. Res.* 95, 642–649. doi: 10.4213/jdent.2016-0516
Huang, G. T., and Garcia-Godoy, F. (2014). Missing concepts in de novo pulp regeneration. J. Dent. Res. 93, 717–724. doi: 10.1177/0022034514537829

Huang, G. T., Gronthos, S., and Shi, S. (2009). Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J. Dent. Res. 88, 792–806. doi: 10.1177/0022034509340076

Ianus, A., Holz, G. G., Theise, N. D., and Hussain, M. A. (2003). In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J. Clin. Invest. 111, 843–850. doi: 10.1128/JCIM200316502

Iida, K., Takeda-Kawaguchi, T., Tetzuka, Y., Kusisada, T., Shibata, T., and Tetzuka, K. (2010). Hyposia enhances colony formation and proliferation but inhibits differentiation of human dental pulp cells. Arch. Oral Biol. 55, 648–654. doi: 10.1016/j.archoralbio.2010.06.005

Inoue, T., Sugiyama, M., Hattori, H., Wakita, H., Wakabayashi, T., and Ueda, M. (2013). Stem cells from human exfoliated deciduous tooth-derived conditioned medium enhance recovery of focal cerebral ischemia in rats. Tissue Eng. Part A 19, 24–29. doi: 10.1089/tiss.2011.0385

Introna, M., Lucchini, G., Dander, E., Galimberti, S., Rovelli, A., Balduzzi, A., et al. (2014). Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol. Blood Marrow Transplant. 20, 375–381. doi: 10.1016/j.bbmt.2013.11.033

Izumoto-Akita, T., Tsunekawa, S., Yamamoto, A., Uemini, E., Ishikawa, K., Ogata, H., et al. (2015). Secreted factors from dental pulp stem cells improve glucose intolerance in streptozocin-induced diabetic mice by increasing peripheral beta-cell function. J. RSMJ Oral Diseases Res. Care 3:e001284

Jalali, M., Kirkpatrick, W. N., Cameron, M. G., Paulkin, S., and Vallier, L. (2014). Human stem cells for craniomaxillofacial reconstruction. Stem Cells Dev. 23, 1437–1451. doi: 10.1089/scd.2013.0576

Janebodin, K., Zeng, Y., Buranapatthawana, W., Ieronimakis, N., and Reyes, M. (2013). VEGFR2-dependent angiogenic capacity of pericyte-like dental pulp stem cells. J. Dent. Res. 92, 524–531. doi: 10.1177/0022034513485599

Karaoz, E., Demircan, P. C., Saglam, O., Aksoy, A., Kaymaz, F., and Durak, G. (2011). Human dental pulp stem cells demonstrate better neural and epithelial stem cell properties than bone marrow-derived mesenchymal stem cells. Histochem. Cell Biol. 136, 455–473. doi: 10.1007/s00418-011-0858-3

Kasper, G., Mao, L., Geissler, S., Draycheva, A., Trippens, J., Kuhnisch, J., and Roewer, C. (2009). Insights into mesenchymal stem cell aging: involvement of antioxidant defense and actin cytoskeleton. Stem Cells 27, 1288–1297. doi: 10.1002/stem.49

Kaukua, N., Chen, M., Guarnieri, P., Dahl, M., Lim, M. L., Yucel-Lindberg, T., et al. (2015). Molecular differences between stromal cell populations from deciduous and permanent human teeth. Stem Cell Res. Ther. 6:39. doi: 10.1186/s13287-015-0056-7

Kaukua, N., Shahidi, M. K., Konstantinidou, C., Dyachuk, V., Kaucka, M., Furlan, A., et al. (2014). Glial origin of mesenchymal stem cells in a tooth model system. Nature 513, 551–554. doi: 10.1038/nature13536

Kawamura, R., Hayashi, Y., Murakami, H., and Nakashima, M. (2016). EDTA regeneration. J. Dent. Res. 95, 646–652. doi: 10.1177/002203451560867

Khojasteh, A., Esmaeelinejad, M., and Aghdash, F. (2015). Regenerative Techniques in Oral and Maxillofacial Bone Grafting. A textbook of Advanced Oral and Maxillofacial Surgery. ed Mo. H. K. Motamedi (London, UK: IntechOpen). 513–547. doi: 10.5772/59236. Available online at: https://www.intechopen.com/books/a-textbook-of-advanced-oral-and-maxillofacial-surgery-volume-2/regenerative-techniques-in-oral-and-maxillofacial-bone-grafting

Khoshkam, V., Chan, H. L., Lin, G. H., MacEachern, M. P., Monje, A., Suarez, F., et al. (2013). Reconstructive procedures for treating peri-implantitis: a systematic review. J. Dent. Res. 92(12Suppl.), 131S–138S. doi: 10.1177/0022034513509279

Kim, J. H., Kim, G. H., Kim, J. W., Pyeon, H. J., Lee, J. C., Lee, G., et al. (2016). In vivo angiogenic capacity of stem cells from human exfoliated deciduous
teeth with human umbilical vein endothelial cells. Mol. Cells 39, 790–796. doi: 10.14348/molcells.2016.0131

Kinkaid, H. Y., Huang, X. P., Li, R. K., and Weisel, R. D. (2010). What’s new in cardiac cell therapy? Allogeneic bone marrow stromal cells as “universal donor cells”. J. Card Surg. 25, 359–366. doi: 10.1111/j.1540-8191.2009.00844.x

Koblas, T., Zacharovova, K., Berkova, Z., Leonovtc, I., Dovololova, E., Zamecnik, L., et al. (2009). In vivo differentiation of human umbilical cord blood-derived cells into insulin-producing beta cells. Folia Biol. 55, 224–232.

Korbling, M., and Estrov, Z. (2003). Adult stem cells for tissue repair – a new therapeutic concept? N. Engl. J. Med. 349, 570–582. doi: 10.1056/NEJMra022361

Kumasaka, A., Kanazawa, K., Ohke, H., Miura, I., and Miura, Y. (2017). Post-ischemic intravenous administration of allogeneic dental pulp-derived neurosphere cells ameliorated outcomes of severe forebrain ischemia in rats. Neurocrit. Care 26, 133–142. doi: 10.1016/j.neucli.2016.03-040-4

Kushnerev, E., Shawcross, S. G., Sotirachagan, S., Carley, F., Brahma, A., Yates, J. M., et al. (2016). Regeneration of corneal epithelium with dental pulp stem cells using a contact lens delivery system. Invest. Ophthalmol. Vis. Sci. 57, 5192–5199. doi: 10.1167/iovs.15-17953

Kwack, K. H., Lee, J. M., Park, S. H., and Lee, H. W. (2017). Human dental pulp stem cells suppress alloantigen-induced immunity by stimulating t cells to release transforming growth factor beta. J. Endod. 43, 100–108. doi: 10.1016/j.joen.2016.09.005

La Noce, M., Mele, L., Tirino, V., Paino, F., De Rosa, A., Naddeo, P., et al. (2014a). Neural crest stem cell population in craniomaxillofacial development and tissue repair. Eur. Cell. Mater. 28, 348–357. doi: 10.22203/ecm.v028a24

La Noce, M., Paino, F., Spina, A., Naddeo, P., Montella, R., Desiderio, V., et al. (2014b). Dental pulp stem cells: state of the art and suggestions for a true translation of research into therapy. J. Dent. 42, 761–768. doi: 10.1016/j.jdent.2014.02.018

Larsson, L., Decker, A. M., Nibali, L., Pinchuk, S. P., Berglundh, T., and Giannobile, W. V. (2016). Regenerative medicine for periodontal and peri-implant diseases. J. Dent. Res. 95, 255–266. doi: 10.1177/0022034515618887

Lee, J. S., An, S. Y., Kwon, I. K., and Heo, J. S. (2014). Transdifferentiation of human dental pulp stem cells from inflammatory dental pulp tissues. J. Diabetes 1, 177–187. doi: 10.5966/sctm.2011-0039

Li, Y., Zhang, S., Nan, X., Wei, H., Shi, J., Li, A., et al. (2015). Transplantation of dental pulp stem cells suppressed inflammation in sciatic nerves by promoting macrophage polarization towards anti-inflammatory phenotypes and ameliorated diabetic polyneuropathy. J. Diabetes Invest. 7, 485–496. doi: 10.1111/jdi.12452

Mason, C., and Dunnill, P. (2009). Assessing the value of autologous and allogeneic cells for regenerative medicine. Regen. Med. 4, 835–853. doi: 10.2217/rme.09.64

Menard, C., Pacelli, L., Bassi, G., Dulong, J., Bifari, F., Bezier, I., et al. (2013). Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev. 22, 1789–1801. doi: 10.1089/scd.2012.0594

Menard, C., and Tarte, K. (2013). Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Res. Ther. 4:64. doi: 10.1186/scrt214

Miller, M. Q., Dighe, A., Cui, Q., Park, S. S., and Christophel, J. J. (2016). Regenerative medicine in facial plastic and reconstructive surgery: a review. JAMA Facial Plast. Surg. 18, 391–394. doi: 10.1001/jamafacial.2016.0913

Miura, M., Gronthos, S., Zhao, M., Lu, B., Fisher, L. W., Robey, P. G., et al. (2003). SHED: stem cells from human exfoliated deciduous teeth. Proc. Natl. Acad. Sci. U.S.A. 100, 5807–5812. doi: 10.1073/pnas.0301225101

Mombelli, A., Muller, N., and Cionca, N. (2012). The epidemiology of peri-implantitis. Clin. Oral Implant Res. 23(Suppl. 6), 67–76. doi: 10.1111/j.1500-8102.2012.02541.x

Morikawa, S., Ouchi, T., Shibata, S., Fujimura, T., Kawana, H., Okano, H., et al. (2016). Applications of mesenchymal stem cells and neural crest cells in craniofacial skeletal research. Stem Cells Int. 2016:2849879. doi: 10.1155/2016/2849879

Neklep, N., Wang, J., Miyatsuka, T., and German, M. S. (2008). Signals from the neural crest regulate beta-cell mass in the pancreas. Development 135, 2151–2160. doi: 10.1242/dev.018359

Okura, H., Komoda, H., Fumimoto, Y., Lee, C. M., Nishida, T., Sawa, Y., et al. (2009). Transdifferentiation of human adipose tissue-derived stromal cells into insulin-producing clusters. J. Artif. Organs 12, 125–130. doi: 10.1007/s10497-009-0455-6

Omi, M., Hata, M., Nakamura, N., Miyabe, M., Kobayashi, Y., Kamiya, H., et al. (2016). Transplantation of dental pulp stem cells suppressed inflammation in sciatic nerves by promoting macrophage polarization towards anti-inflammation phenotypes and ameliorated diabetic polyneuropathy. J. Diabetes Investig. 7, 485–496. doi: 10.1111/jdi.12452

Otsathanon, T., Sawangmake, C., Nowwarote, N., and Pavasant, P. (2014). Neurogenic differentiation of human dental pulp stem cells using different induction protocols. Oral Dis. 20, 352–358. doi: 10.1111/odi.12119

Pacini, S. (2014). Deterministic and stochastic approaches in the clinical application of mesenchymal stromal cells (MSCs). Front. Cell. Dev. Biol. 2:50. doi: 10.3389/fcell.2014.00050

Pall, O., Varga, B., Collart-Dutilleul, P. Y., Gergely, C., and Cuisinier, F. J. G. (2017). “an overview of protocols for the neural induction of dental and oral stem cells in vitro” by Heng et al. (Tissue Eng Part B 2016;22:220-250). Tissue Eng. B Rev. 23, 570–576. doi: 10.1089/ten.TEB.2016.0512

Papaccio, G., Graziano, A., d’Aquino, R., Graziano, M. F., Pirozzi, G., Menditti, D., et al. (2006). Long-term cryopreservation of dental pulp stem cells (PB-DPCs) and their differentiated osteoblasts: a cell source for tissue repair. J. Cell. Physiol. 208, 319–325. doi: 10.1002/jcp.20667

Perry, B. C., Zhou, D., Wu, X., Yang, F. C., Byers, M. A., Chu, T. M., et al. (2008). Collection, cryopreservation, and characterization of human dental pulp-derived mesenchymal stem cells for banking and clinical use. Tissue Eng. Part C Methods 14, 149–156. doi: 10.1089/tenc.2008.0031

Pierdomenico, L., Bonsi, L., Calvitti, M., Rondelli, D., Arpinati, M., Chirumbolo, G., et al. (2005). Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp. J. Diabetes 135, 12119.

Piscitella, A., Riccio, M., Carnevale, G., Lu, A., De Biasi, S., Gibellini, L., et al. (2015). Stem cells isolated from human dental pulp and amniotic fluid improve skeletal muscle histopathology in mdx/SCID mice. Stem Cell Res. Ther. 6:156. doi: 10.1186/s13287-015-0141-y
Rahman, I., Said, D. G., Maharajan, V. S., and Dua, H. S. (2009). Anomniotic membrane in ophthalmology: indications and limitations. Eye 23, 1954–1961. doi: 10.1038/eye.2008.410

Rajan, T. S., Giacoppo, S., Diomede, F., Balleirini, P., Paolantonio, M., Marchisio, M., et al. (2016). The secretome of periodontal ligament stem cells from MS patients protects against EAE. Sci. Rep. 6, 38473. doi: 10.1038/srep38473

Rama, P., Matsuoka, S., Paganoni, G., Spinnelli, A., De Luca, M., and Pellegrini, G. (2010). Limbal stem-cell therapy and long-term corneal regeneration. N. Engl. J. Med. 363, 147–155. doi: 10.1056/NEJMoa095955

Ramirez, B. E., Sanchez, A., Herreras, J. M., Fernandez, I., Garcia-Sanchez, J., Nieto-Miguel, T., et al. (2015). Stem cell therapy for corneal epithelial regeneration following good manufacturing and clinical procedures. Biomed. Res. Int. 2015:408495. doi: 10.1155/2015/408495

Ricardo, J. R., Cristovam, P. C., Filho, P. A., Farias, C. C., de Araujo, A. L., Loureiro, R. R., et al. (2013). Transplantation of conjunctival epithelial cells cultivated ex vivo in patients with total limbal stem cell deficiency. Cornea 32, 221–228. doi: 10.1097/ICO.0b013e3182503436

Sacai, K., Yamamoto, A., Matsubara, K., Nakamura, S., Naruse, M., Yamagata, M., et al. (2012). Human dental pulp-derived stem cells promote locomotor recovery after complete transection of the rat spinal cord by multiple neuro-regenerative mechanisms. J. Clin. Invest. 122, 80–90. doi: 10.1172/JCI59251

Sanchez-Siles, M., Ballester-Ferrandis, J. F., Salazar-Sanchez, N., Gomez-Garcia, F. J., Moraleja-Ruiz, R., and Camacho-Alonso, F. (2018). Long-term evaluation of quality of life and satisfaction between implant bar overdentures and conventional complete dentures: a 23 years retrospective study. Clin. Implant Dent. Relat. Res. 20, 208–214. doi: 10.1111/cid.12576

Sanen, K., Martens, W., Georgiou, M., Ameloot, M., Lambrecht, I., and Phillips, J. (2017). Engineered neural tissue with Schwann cell differentiated human dental pulp stem cells: potential for peripheral nerve repair? J. Tissue Eng. Regen. Med. 11, 3362–3372. doi: 10.1002/crm2.2249

Sasaki, R., Aoki, S., Yamato, M., Uchiyama, H., Wada, K., Oguchi, H., et al. (2011). PLGA artificial nerve conduits with dental pulp cells promote facial nerve regeneration. J. Tissue Eng. Regen. Med. 5, 823–830. doi: 10.1087/3878

Schnutenhaus, S., Edelmann, C., Rudolph, H., Dreyhaupt, J., and Luthardt, R. G. (2018). 3D accuracy of implant positions in template-guided implant placement as a function of the remaining teeth and the surgical procedure: a retrospective study. Clin. Oral Investig. 10, 207–214. doi: 10.1007/s00784-014-1577-6

Schonhoff, S. E., Giel-Moloney, M., and Leiter, A. B. (2004). Minireview: development and differentiation of gut endocrine cells. Endocrinology 145, 2639–2644. doi: 10.1210/en.2004-0051

Shapiro, A. M., Lakey, J. R., Ryan, E. A., Korbott, G. S., Toth, E., Warnock, G. L., et al. (2000). Islet transplantation in seven patients with type 1 diabetes mellitus and the immunobiology of insulin allografts: a clinical appraisal of the first human trials. Tissue Eng. 6:38743. doi: 10.1038/srep03874

Sonoyama, W., Liu, Y., Fang, D., Yamaza, T., Seo, B. M., Zhang, C., et al. (2016). Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS ONE 11:e0179. doi: 10.1371/journal.pone.0000079

Surkus, A., Hoge, J. A., DiazGranados, D., Hunt, J. D., Mazmanian, P. E., Connors, E., et al. (2016). Classifying publications from the clinical and translational science award program along the translational research spectrum: a machine learning approach. J. Transl. Med. 14:235. doi: 10.1186/s12967-016-0992-8

Syed-Picard, F. N., Du, Y., Lathrop, K. L., Mann, M. M., Funderburgh, M. L., and Funderburgh, J. L. (2015). Dental pulp stem cells: a new cellular resource for corneal stromal regeneration. Stem Cells Transl. Med. 4, 276–285. doi: 10.5966/sctm.2014-0115

Talip, P., Aydin, S., and Sahin, F. (2016). "Immunomodulatory properties of stem cells derived from dental tissues,” in Dental Stem Cells, Stem Cell Biology and Regenerative Medicine, eds F. Sahin, A. Dogan, and S. Demirci (Basel: Springer International Publishing), 29–45.
Zhang, J., An, Y., Gao, L. N., Zhang, Y. J., Jin, Y., and Chen, F. M. (2012). The effect of aging on the pluripotential capacity and regenerative potential of human periodontal ligament stem cells. *Biomaterials* 33, 6974–6986. doi: 10.1016/j.biomaterials.2012.06.032

Zhang, N., Chen, B., Wang, W., Chen, C., Kang, J., Deng, S. Q., et al. (2016). Isolation, characterization and multi-lineage differentiation of stem cells from human exfoliated deciduous teeth. *Mol. Med. Rep.* 14, 95–102. doi: 10.3892/mmr.2016.5214

Zhou, S., Greenberger, J. S., Epperly, M. W., Goff, J. P., Adler, C., Leboff, M. S., et al. (2008). Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. *Aging Cell* 7, 335–343. doi: 10.1111/j.1474-9726.2008.00377.x

Zhuo, Y., Li, S. H., Chen, M. S., Wu, J., Kinkaid, H. Y., Fazel, S., et al. (2010). Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. *J. Thorac. Cardiovasc. Surg.* 139, 1286–1294, 1294.e1281–1282. doi: 10.1016/j.jtcvs.2009.08.052

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Marei and El Backly. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.